MELI vs NKE: Which Is the Better Buy?

Side-by-side comparison of MercadoLibre, Inc. and NIKE, Inc. β€” fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-04-11.
MercadoLibre, Inc. Β· Consumer Cyclical
$1,767.42
+41.4% upside to fair value
High Conviction Grade A
VS
NIKE, Inc. Β· Consumer Cyclical
$42.62
+45.5% upside to fair value
Med Conviction Grade B+
QuantHub Verdict
NKE has more upside to fair value (+45.5%). NKE trades at a lower forward P/E (27.9x). These are model outputs β€” not personalized investment advice. See all research β†’
Valuation & Fundamentals
Metric MELI NKE
Current Price $1,767.42 $42.62
Fair Value Estimate $2,500.00 $62.00
Upside to Fair Value +41.4% +45.5%
Market Cap $89.6B $63.0B
Forward P/E 35.0x 27.9x
EV / EBITDA 18.5x 20.7x
Price / Sales 3.1x 1.4x
Price / FCF 8.9x 19.4x
Revenue Growth YoY +39.1% -9.8%
Gross Margin 44.5% 42.7%
Operating Margin 11.1% 8.0%
Return on Equity 33.7% 24.4%
Dividend Yield 0% 3.8%
FCF Yield 12.1% 5.2%
Analyst Consensus Strong Buy Buy
Investment Thesis
MELI β€” MercadoLibre, Inc.
MercadoLibre is the dominant e-commerce and fintech ecosystem across Latin America, operating the largest marketplace and digital payments platform in a region with 670M+ people where e-commerce penetration is still under 15%. Revenue grew 39% to $28.9B in FY2025 with $10.8B in free cash flow β€” a 12% FCF yield at current prices. The company is trading at its 5-year P/S minimum (3.1x) and P/FCF mi…
NKE β€” NIKE, Inc.
Nike is the world's largest athletic footwear and apparel company with $46.3B in FY2025 revenue, operating across 190+ countries with the Nike, Jordan, and Converse brands. The stock trades near its 9-year low at $42.62 after an 11% single-day crash following a Q3 FY2026 earnings report that showed 35% net income decline and weak Q4 guidance calling for a further 2-4% revenue decline. FY2025 reve…
Accumulation Zones
Metric MELI NKE
Zone Low $1,875.00 $44.00
Zone High $2,125.00 $50.00
In Buy Zone? Yes Yes
← MELI Research    NKE Research β†’    All Research